These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 25713431)
1. Oral bisphosphonate use and risk of postmenopausal endometrial cancer. Newcomb PA; Passarelli MN; Phipps AI; Anderson GL; Wactawski-Wende J; Ho GY; O'Sullivan MJ; Chlebowski RT J Clin Oncol; 2015 Apr; 33(10):1186-90. PubMed ID: 25713431 [TBL] [Abstract][Full Text] [Related]
2. Oral bisphosphonate use and lung cancer incidence among postmenopausal women. Tao MH; Chen S; Freudenheim JL; Cauley JA; Johnson KC; Mai X; Sarto GE; Wakelee H; Boffetta P; Wactawski-Wende J Ann Oncol; 2018 Jun; 29(6):1476-1485. PubMed ID: 29617712 [TBL] [Abstract][Full Text] [Related]
3. Oral bisphosphonate use and colorectal cancer incidence in the Women's Health Initiative. Passarelli MN; Newcomb PA; LaCroix AZ; Lane DS; Ho GY; Chlebowski RT J Bone Miner Res; 2013 Sep; 28(9):2043-8. PubMed ID: 23519920 [TBL] [Abstract][Full Text] [Related]
4. Effect of oral bisphosphonates for osteoporosis on development of skeletal metastases in women with breast cancer: results from a pharmaco-epidemiological study. Kremer R; Gagnon B; Meguerditchian AN; Nadeau L; Mayo N J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25278509 [TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer. Ito K; Blinder VS; Elkin EB J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313 [TBL] [Abstract][Full Text] [Related]
6. The effect of bisphosphonates on the risk of endometrial and ovarian malignancies. Rennert G; Rennert HS; Pinchev M; Lavie O Gynecol Oncol; 2014 May; 133(2):309-13. PubMed ID: 24556062 [TBL] [Abstract][Full Text] [Related]
7. Bisphosphonate use and the risk of endometrial cancer: a meta-analysis of observational studies. Ou YJ; Chiu HF; Wong YH; Yang YH Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1107-1115. PubMed ID: 27501339 [TBL] [Abstract][Full Text] [Related]
8. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. Chlebowski RT; Chen Z; Cauley JA; Anderson G; Rodabough RJ; McTiernan A; Lane DS; Manson JE; Snetselaar L; Yasmeen S; O'Sullivan MJ; Safford M; Hendrix SL; Wallace RB J Clin Oncol; 2010 Aug; 28(22):3582-90. PubMed ID: 20567009 [TBL] [Abstract][Full Text] [Related]
9. Protective effect of bisphosphonates on endometrial cancer incidence in data from the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial. Alford SH; Rattan R; Buekers TE; Munkarah AR Cancer; 2015 Feb; 121(3):441-7. PubMed ID: 25533883 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates. Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128 [TBL] [Abstract][Full Text] [Related]
11. Estimating bisphosphonate use and fracture reduction among US women aged 45 years and older, 2001-2008. Siris ES; Pasquale MK; Wang Y; Watts NB J Bone Miner Res; 2011 Jan; 26(1):3-11. PubMed ID: 20662073 [TBL] [Abstract][Full Text] [Related]
12. Prospective study of leukocyte count as a predictor of incident breast, colorectal, endometrial, and lung cancer and mortality in postmenopausal women. Margolis KL; Rodabough RJ; Thomson CA; Lopez AM; McTiernan A; Arch Intern Med; 2007 Sep; 167(17):1837-44. PubMed ID: 17893304 [TBL] [Abstract][Full Text] [Related]
13. Long-term oral bisphosphonate use in relation to fracture risk in postmenopausal women with breast cancer: findings from the Women's Health Initiative. Drieling RL; LaCroix AZ; Beresford SA; Boudreau DM; Kooperberg C; Chlebowski RT; Gass M; Crandall CJ; Womack CR; Heckbert SR Menopause; 2016 Nov; 23(11):1168-1175. PubMed ID: 27433859 [TBL] [Abstract][Full Text] [Related]
14. Bisphosphonate use and the risk of breast cancer: a meta-analysis of published literature. Liu Y; Zhao S; Chen W; Hu F; Zhu L; Zhang Q; Zhao Y Clin Breast Cancer; 2012 Aug; 12(4):276-81. PubMed ID: 22622199 [TBL] [Abstract][Full Text] [Related]
15. Is Endometrial Cancer Risk Reduced by Oral Bisphosphonate Use? Tomao F; Colombo N; Panici B J Clin Oncol; 2015 Nov; 33(31):3670. PubMed ID: 26282662 [No Abstract] [Full Text] [Related]
16. Risk reduction of endometrial and ovarian cancer after bisphosphonates use: A meta-analysis. Zhang XS; Zhang YM; Li B; Fan B; Zhao Y; Yang SJ Gynecol Oncol; 2018 Sep; 150(3):509-514. PubMed ID: 29960711 [TBL] [Abstract][Full Text] [Related]
17. Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment. Sebba AI Clin Ther; 2008 Mar; 30(3):443-52. PubMed ID: 18405784 [TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates in adjuvant setting for breast cancer: a review of the meta-analysis of bisphosphonates' effects on breast cancer recurrence presented in December 2013 at San Antonio Breast Conference. Costa L Curr Opin Support Palliat Care; 2014 Dec; 8(4):414-9. PubMed ID: 25319273 [TBL] [Abstract][Full Text] [Related]
19. Use of bisphosphonates and risk of postmenopausal breast cancer. Rennert G; Pinchev M; Rennert HS J Clin Oncol; 2010 Aug; 28(22):3577-81. PubMed ID: 20567021 [TBL] [Abstract][Full Text] [Related]
20. Body weight in early adulthood, adult weight gain, and risk of endometrial cancer in women not using postmenopausal hormones. Stevens VL; Jacobs EJ; Patel AV; Sun J; Gapstur SM; McCullough ML Cancer Causes Control; 2014 Mar; 25(3):321-8. PubMed ID: 24381074 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]